Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.

CONCLUSION: In the last decade, promising biomarkers have been validated and lead to new therapeutic strategies with PARP inhibitors, immunotherapy and anti-angiogenic agents. Biomarkers such as BRCA, homologus recombination defect (HRD), immuno-markers (CD8, PD-1, PDL-1), KRAS and PR, are now used in clinical trials. Other: Assessment of genetic variants will soon represent the standard-of-care in gynecological cancers, not only to diagnose the disease but also to assist the prediction of clinical behavior of tumors and support personalized medicine to match patients with appropriate targeted therapies, improving treatment efficacy and quality of life for patients. PMID: 31622218 [PubMed - as supplied by publisher]
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research